552 related articles for article (PubMed ID: 32037060)
1. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
3. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
6. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Salama AK; Moschos SJ
Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
[TBL] [Abstract][Full Text] [Related]
7. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
8. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
9. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
11. Biophysical and Immunological Characterization and
Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
[TBL] [Abstract][Full Text] [Related]
12. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Lee HT; Lee SH; Heo YS
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
Konstantinidou M; Zarganes-Tzitzikas T; Magiera-Mularz K; Holak TA; Dömling A
Angew Chem Int Ed Engl; 2018 Apr; 57(18):4840-4848. PubMed ID: 29178534
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
17. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
18. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors.
Hui E
J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
